ESICM,ESCMID，IATDMCT重症患者抗菌药物治疗监测（TDM）.pdf

Intensive Care Med /10.1007/s00134-020-06050-1 CONFERENCE REPORT AND EXPERT PANEL Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# 1 2,3,4 5 6 7 Mohd H. Abdul‑Aziz , Jan‑Willem C. Alfenaar , Matteo Bassetti , Hendrik Bracht , George Dimopoulos , Deborah Marriott8, Michael N. Neely9,10, Jose‑Artur Paiva11,12, Federico Pea13, Fredrik Sjovall14, Jean F. Timsit 15,16, Andrew A. Udy17,18, Sebastian G. Wicha19, Markus Zeitlinger20, Jan J. De Waele21, Jason A. Roberts1,22,23,24* on behalf of the Infection Section of European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/ pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC) © 2020 Springer‑Verlag GmbH Germany, part of Springer Nature Abstract Purpose: This Position Paper aims to review and discuss the available data on therapeutic drug monitoring (TDM) of antibacterials, antifungals and antivirals in critically ill adult patients in the intensive care unit (ICU). This Position Paper also provides a practical guide on how TDM can be applied in routine clinical practice to improve therapeutic outcomes in critically ill adult patients. Methods: Literature review and analysis were performed by Panel Members nominated by the endorsing organi‑ sations, European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/Pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), International